{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q1 FY27)",
      "prediction": "BEAT",
      "answer": "pred ~$2.56 vs. cons $2.52",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q1 FY27)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.50B vs. cons $1.51B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "AST constant-currency organic growth (Q1 FY27)",
      "prediction": "MISS",
      "answer": "pred ~+4% vs. cons ~+6.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY27 Adjusted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$11.10-$11.30 (mid ~$11.20) vs. cons ~$11.20 (FY2027)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY27 constant-currency organic revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~+6-7% (mid ~6.5%) vs. cons ~+6.5% (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY27 as-reported revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~+7-8% (mid ~7.5%) vs. cons ~+7.5% (FY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.5,
  "day5_path": "FADE",
  "day5_rationale": "STE enters the print up ~10% idiosyncratically in late July (SPY flat), re-rating expectations into a quarter management itself framed as a soft, back-half-weighted start. Likely outcome is a modest EPS beat but decelerating headline/AST organic growth against tough comps (AST +13%/Healthcare service +13% last Q1), higher ~25% tax rate compressing conversion, and lighter FCF. A 'beat-and-reaffirm' (not raise) early in the fiscal year gives the tape little new to chase; out-period math (soft H1, dependence on unproven H2 AST reacceleration and med-tech destocking bottoming) invites near-term estimate trimming even after a beat, so the run-up fades toward pre-rally levels absent a confident H2 message.",
  "day5_confidence": "LOW"
}